Neurological Complications of COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Global functional outcomes using modified Rankin score
研究概览
简要总结
This study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (COVID-19).
详细描述
This study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (COVID-19). Severe acute respiratory syndrome 2 (SARS-CoV-2), the virus that causes COVID-19, shares significant structural and biological similarities with SARS-CoV, which is known to be neuroinvasive particularly with brainstem involvement. There are emerging reports of neurological symptoms associated with COVID-19 infections, including seizures, coma, encephalitis, Guillan-Barre syndrome, and cerebrovascular events including ischemic stroke, ICH, and cerebral venous sinus thromboses. However, the exact prevalence of these conditions and their impact on patient disease severity and outcomes is unknown. As the incidence and severity of COVID-19 infection continue to rapidly rise globally, it is imperative to capture prospective data to accurately document prevalence, severity and clinical characterization of neurological components of COVID 19, the influence of treatment regimens of neurological complications, and role of these confounders on patient and organizational outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients greater than or equal to 18 years old
- •Admitted with suspected or confirmed COVID19 infection
- •Patient exhibiting acute neurological symptoms
排除标准
- •Patients under the age of 18 years old
- •Pre-existing, baseline severe neurologic dysfunction including baseline coma/vegetative state, baseline quadriparesis, baseline refractory seizure disorder with frequent breakthrough seizures despite anticonvulsant use
结局指标
主要结局
Global functional outcomes using modified Rankin score
时间窗: At hospital discharge, approximately 1 month
Patients will be assessed on a scale score of 0 (no symptoms at all) to 5 (severe disability; bedridden, incontinent and requiring constant nursing care and attention)
Prevalence of neurological manifestations
时间窗: During hospital course, up to 1 month
Proportion of patients with neurological symptoms out of all hospitalized COVID19 patients during study period.
Hospital Mortality
时间窗: At hospital discharge, approximately 1 month
次要结局
- Length of ICU stay(At hospital discharge, approximately 1 month)
- 30-day mortality(30 days from the first day of hospitalization)
- Length of hospital stay (in days)(At hospital discharge, approximately 1 month)
- 90-day mortality(90 days from the first day of hospitalization)
研究者
Sherry Hsiang-Yi Chou
Associate Professor
University of Pittsburgh
